Financing, Equity Capital Markets

TCR2 Therapeutics

07/20
|
$142.6 Million
Piper Sandler served as bookrunner for TCR2 Therapeutics on a follow-on offering
Sub-Type
Follow-On Offering
Sub-Sector
Biopharma